Financing ·
Jazz Pharmaceuticals extends maturity to May 2033 and reprices $1.895B term loan B-3 with reduced margins
JAZZJazz Pharmaceuticals plc
On September 23, 2026, Jazz Pharmaceuticals plc extended the maturity of its U.S. dollar term loan B-2 facility to May 5, 2033, and repriced the debt through Amendment No. 4 to its Credit Agreement. Existing lenders converted outstanding Tranche B-2 loans into a new Tranche B-3 tranche with substantially similar terms but reduced margins: 1.75% over Term SOFR (down 50 basis points) or 0.75% over the prime lending rate, subject to a 0.50% SOFR floor. The company borrowed an additional $273,310,355.18 in Tranche B-3 loans to repay non-converted balances, bringing the total principal of the new tranche to $1,895,000,000. The debt amortizes quarterly at 0.25% of the initial principal amount. Jazz Pharmaceuticals plc operates in the pharmaceutical industry, developing and commercializing medicines for rare diseases.